| Literature DB >> 30423820 |
Min Liu1, Zhi-Hui Yang2, Guo-Hui Li3.
Abstract
A novel, precise, and accurate high-performance liquid chromatography-tandem mass spectrometry (Q-trap-MS) method was developed, optimized, and validated for determination of vancomycin in human serum using norvancomycin as an internal standard. Effect of different parameters on the analysis was evaluated. ZORBAX SB-C18 column (150 × 4.6 mm, 5 μm) using water (containing 0.1% formic acid, v/v)⁻acetonitrile (containing 0.1% formic acid, v/v) as a mobile phase was chosen. The calibration curve was linear over the concentration ranges of 1 to 2000 ng/mL for vancomycin. The limit of detection (LOD) and limit of quantification (LOQ) for vancomycin were 0.3 and 1.0 ng/mL. Recoveries were between 87.2 and 102.3%, which gave satisfactory precision. A total of 100 serum samples (from 50 patients with diabetic foot proven Gram-positive infection and 50 nondiabetic patients with pneumonia requiring hospitalization and antibiotic therapy) were analyzed by this method. The trough vancomycin concentrations of diabetic foot infection (DFI) patients and nondiabetic patients were 8.20 ± 2.83 μg/mL (range: 4.80⁻14.2 μg/mL) and 15.80 ± 5.43 μg/mL (range: 8.60⁻19.5 μg/mL), respectively. The method is sensitive, precise, and reproducible, it could be applied for routine laboratory analysis of vancomycin in serum samples.Entities:
Keywords: Diabetic Foot Infection (DFI); MRSA; Serum; high performance liquid chromatography—tandem mass spectrometry; norvancomycin; vancomycin
Mesh:
Substances:
Year: 2018 PMID: 30423820 PMCID: PMC6278353 DOI: 10.3390/molecules23112939
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of vancomycin and norvancomycin.
Figure 2Product ion mass spectra of [M + H]2+ for (a) vancomycin (718.8 → 144.3, 99.7) and (b) norvancomycin (725.6 → 144.1, 100.1).
Figure 3Typical chromatograms of (a) blank serum, (b) vancomycin standard in deionized water (500 ng/mL), (c) vancomycin standard in serum (patients after treated with vancomycin), (d) blank sample spiked with vancomycin (1 ng/mL).
Intra and interday precision and accuracy of vancomycin in serum.
| Concentration (ng/mL) | Intraday ( | Interday ( | ||||
|---|---|---|---|---|---|---|
| Measured Conc (ng/mL) | Precision, RSD (%) | Accuracy (%) | Measured Conc (ng/mL) | Precision RSD (%) | Accuracy (%) | |
| 400 | 396.66 ± 22.17 | 3.21 | 99.17 | 394.38 ± 23.75 | 4.11 | 98.60 |
| 20 | 20.98 ± 1.52 | 5.17 | 104.90 | 21.14 ± 1.91 | 5.86 | 105.70 |
| 2 | 2.10 ± 0.19 | 6.67 | 105.00 | 1.99 ± 0.18 | 7.14 | 99.50 |
Extraction recovery of vancomycin in serum.
| Analyte | Concentration (ng/mL) | Extraction Recovery (%) | |
|---|---|---|---|
| Mean ± SD | RSD | ||
| Vancomycin | 400 | 99.72 ± 2.23 | 1.26 |
| 20 | 94.94 ± 3.88 | 1.59 | |
| 2 | 92.51 ± 4.18 | 3.67 | |
Stability of vancomycin in serum under various storage conditions.
| Storage Condition | Concentration (ng/L) | Mean ± SD (ng/L) | RSD % |
|---|---|---|---|
| Autosampler (4 °C) temperature for 24 h | 2 | 2.20 ± 0.21 | 8.76 |
| 20 | 21.67 ± 1.92 | 8.13 | |
| 400 | 408.16 ± 7.88 | 2.19 | |
| Room temperature (25 °C) for 24 h | 2 | 2.24 ± 0.25 | 3.33 |
| 20 | 22.14 ± 2.24 | 6.51 | |
| 400 | 406.12 ± 6.92 | 2.26 | |
| −80 °C for 30 days | 2 | 2.29 ± 0.24 | 8.91 |
| 20 | 21.01 ± 1.73 | 8.77 | |
| 400 | 420.11 ± 7.95 | 2.11 | |
| Freezing and thawing cycles | 2 | 2.30 ± 0.21 | 8.12 |
| 20 | 22.18 ± 1.77 | 6.51 | |
| 400 | 411.187 ± 9.91 | 1.52 |
Comparison of DFI group and nondiabetic group.
| DFI Group | Nondiabetic Group | χ2/t |
| |
|---|---|---|---|---|
| Samples of achieving target trough concentration | 18(36.0%) | 40(80.0%) | 5.386 | 0.020 |
| Trough Concentration of vancomycin (μg/mL) | 8.20 ± 2.83 | 15.8 ± 5.43 | 3.781 | 0.004 |
| ClCr (mL/min) | 126.14 ± 42.36 | 105.76 ± 38.66 | 2.891 | 0.005 |